An example of cytisine overdose with no consequent side-effects: a case report.

Autor: Campagnari S; Department of Internal Medicine, Addiction Unit, Verona University Hospital, Verona, Italy., Zamboni L; Department of Internal Medicine, Addiction Unit, Verona University Hospital, Verona, Italy. Lorenzo.zamboni88@gmail.com.; Department of Neurosciences, University of Verona, Verona, Italy. Lorenzo.zamboni88@gmail.com., Barbon I; Department of Internal Medicine, Addiction Unit, Verona University Hospital, Verona, Italy., Fusina F; Department of General Psychology, University of Padova, Padua, Italy.; Padova Neuroscience Center, University of Padova, Padua, Italy., Lugoboni F; Department of Internal Medicine, Addiction Unit, Verona University Hospital, Verona, Italy.
Jazyk: angličtina
Zdroj: Journal of medical case reports [J Med Case Rep] 2024 Nov 29; Vol. 18 (1), pp. 578. Date of Electronic Publication: 2024 Nov 29.
DOI: 10.1186/s13256-024-04938-w
Abstrakt: Background: Cytisine is an alkaloid that is molecularly similar to nicotine and it is commonly used to treat smoking cessation. While it is considered a reasonably safe treatment option, cytisine intoxication in humans exhibits several adverse effects. These involve the gastrointestinal system (nausea, vomiting, diarrhea), the central nervous system (drowsiness, fatigue, delirium), and the motor system (muscle twitching and fasciculation, difficulties in walking).
Case Presentation: We present a unique case report in which a Caucasian patient (an Italian 64-year-old woman) who was undergoing smoking cessation treatment with cytisine, and due to her misunderstanding of the therapeutic indications provided, took twice the recommended dose every day for 8 days, leading to an intake of 54 mg/dl of cytisine for 3 consecutive days. Notwithstanding the high dosage, the patient did not report any adverse reactions.
Conclusion: This confirms the safety of the drug, even at high doses, in patients aiming to quit smoking.
Competing Interests: Declarations. Ethics approval and consent to participate: This study was approved by the Ethical Review Board of the University Hospital (approval code 683CESC). Consent for publication: Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal. Competing interests: None.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje